ThermoGenesis Holdings to Announce Financial Results for the Year Ended December 31, 2022 and Provide a Corporate Strategic Update
ThermoGenesis Holdings, Inc. (THMO) announced it will release its financial results for the year ending December 31, 2022, on March 30, 2023.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ThermoGenesis Holdings, Inc. (THMO) announced it will release its financial results for the year ending December 31, 2022, on March 30, 2023. The release will include a corporate strategic update following the market close. A conference call is scheduled for the same day at 1:30 p.m. PT (4:30 p.m. ET), accessible via phone or live webcast. ThermoGenesis specializes in automated technologies for CAR-T and other cell-based therapies, offering solutions for automated clinical biobanking and immuno-oncology. Investors can access a webcast replay on the company’s website for three months following the event.
Positive
- Scheduled release of financial results indicates transparency and engagement with investors.
- Focused on CAR-T and cell-based therapies, suggesting potential growth in the biopharmaceutical market.
Negative
- None.
Details
News Market Reaction – THMO
The recorded move for THMO in the trading session of this news was -15.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call to be Held on March 30, 2023
RANCHO CORDOVA, Calif., March 28, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release its financial results for the year ended December 31, 2022 and provide a corporate strategic update on Thursday, March 30, 2023, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET.
To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: https://thermogenesis.com/investors/news-and-events/events-webcasts/.
A webcast replay will be available on ThermoGenesis' website for three months by visiting the Investor page of the Company's website at www.thermogenesis.com.
About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.
Company Contact:
Wendy Samford
916-858-5191
ir@ThermoGenesis.com
Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
View original content:https://www.prnewswire.com/news-releases/thermogenesis-holdings-to-announce-financial-results-for-the-year-ended-december-31-2022-and-provide-a-corporate-strategic-update-301783044.html
SOURCE ThermoGenesis Holdings, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.